Vanguard Group Inc cut its position in BioXcel Therapeutics Inc (NASDAQ:BTAI) by 1.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 296,233 shares of the company’s stock after selling 4,565 shares during the period. Vanguard Group Inc owned approximately 1.89% of BioXcel Therapeutics worth $2,269,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in the company. Creative Planning bought a new stake in shares of BioXcel Therapeutics in the third quarter worth approximately $102,000. BlackRock Inc. bought a new stake in shares of BioXcel Therapeutics in the second quarter worth approximately $137,000. Finally, Artemis Investment Management LLP grew its stake in shares of BioXcel Therapeutics by 1.3% in the third quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock worth $9,700,000 after acquiring an additional 16,358 shares during the period. Hedge funds and other institutional investors own 20.71% of the company’s stock.
Shares of BTAI stock opened at $8.68 on Friday. BioXcel Therapeutics Inc has a 52 week low of $2.41 and a 52 week high of $14.79.
BTAI has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of BioXcel Therapeutics in a research note on Wednesday, December 12th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $18.67.
In related news, Director Peter Mueller purchased 8,795 shares of BioXcel Therapeutics stock in a transaction dated Friday, December 7th. The stock was purchased at an average cost of $5.01 per share, for a total transaction of $44,062.95. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 19,152 shares of company stock valued at $95,778 over the last quarter.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Want to see what other hedge funds are holding BTAI?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioXcel Therapeutics Inc (NASDAQ:BTAI).
Receive News & Ratings for BioXcel Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioXcel Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.